Life science Related Topics 
McKinsey Public & Social Sector Insights
JANUARY 31, 2023
Life sciences companies are making progress in adopting and deploying digital and analytics. Insights on Life Sciences Pharmaceuticals DigitalBut they can go further and faster by heeding some lessons from the past few years.
McKinsey Public & Social Sector Insights
DECEMBER 14, 2022
As the life sciences industry is tested by an uncertain economic environment, companies can focus not only on resilience but on positioning themselves to accelerate when coming out of the downturn. Insights on Life Sciences Medical products Pharmaceuticals
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
McKinsey Public & Social Sector Insights
AUGUST 3, 2022
For life science companies to meet their digital ambitions, they must strengthen their technology skills. Insights on Life Sciences Health Care Pharmaceuticals DigitalIn a challenging market, emphasizing value propositions can attract first-rate talent.
McKinsey
OCTOBER 28, 2021
As cloud technology matures, life-sciences companies are generating new paths to business value beyond the cost efficiencies that cloud migrations typically target. Insights on Life Sciences Medical products Pharmaceuticals Cloud computing
McKinsey Public & Social Sector Insights
SEPTEMBER 14, 2022
Life sciences companies pursuing a step change in performance have obtained mixed results. Insights on Life Sciences Pharmaceuticals Performance transformationAdhering to five principles can greatly improve the odds of a large transformation program succeeding.
Frost & Sullivan Manufacturing
JANUARY 18, 2023
NetApp brings clear value for payers, healthcare providers, and life sciences companies while ensuring the best outcomes through its customer-centered and data-centric approach. Best Practice Awards Healthcare & Life Sciences Best Practices News Press Releases
Frost & Sullivan Manufacturing
JANUARY 16, 2023
Middle East 2023 Top 5 Trends to Watch in Healthcare & Life Sciences Industry. The post Middle East 2023 Top 5 Trends to Watch in Healthcare & Life Sciences Industry appeared first on Frost & Sullivan.
Frost & Sullivan
JANUARY 31, 2022
31, 2022 – The post COVID-19 pandemic recovery and other geopolitical events in 2021 has left the healthcare & life sciences industry in a remarkable position to be ready for 2022 and beyond. San Antonio, TX, – Jan.
LaVoie Health Science Blog
JULY 16, 2021
Interviews with our senior practice managers about issues of important to life science innovators. As investments into sustainable companies and funds have surged to new highs, how can biotech and life science companies best position themselves with this burgeoning group of investors.
Frost & Sullivan
AUGUST 9, 2021
As life sciences companies aim to enhance patients’ treatment experiences and find new biomarkers that aid drug discovery, DTx companies diversify their pipelines by adding new indications, addressing unmet needs.
Frost & Sullivan
AUGUST 9, 2021
As life sciences companies aim to enhance patients’ treatment experiences and find new biomarkers that aid drug discovery, DTx companies diversify their pipelines by adding new indications, addressing unmet needs.
McKinsey
APRIL 8, 2022
The healthcare sector is examining how to better hire and promote women to the highest levels. Insights on Healthcare Systems & Services Health care providers Pharmaceuticals
Frost & Sullivan Manufacturing
JULY 19, 2022
July 19, 2022- Recently, Frost & Sullivan assessed the life sciences e-commerce industry, and, based on its findings, recognizes ZAGENO with the 2022 Customer Value Leadership Award. Best Practice Awards Healthcare & Life Sciences Best Practices News Press Releases
Frost & Sullivan
AUGUST 5, 2021
LifeSphere supports hundreds of global life sciences companies to accelerate development, maintain compliance, and streamline collaboration between cross-functional teams. Best Practice Awards Healthcare & Life Sciences Best Practices News Press Releases
McKinsey Public & Social Sector Insights
JANUARY 27, 2023
Digital and analytics can markedly improve life sciences companies’ engagement with customers. Insights on Life Sciences Pharmaceuticals Digital strategy and organization
Frost & Sullivan
FEBRUARY 8, 2021
To help companies identify new avenues for top-line growth and plan for a more fruitful 2021, Frost & Sullivan’s team of industry experts have compiled a complimentary insight: Top 8 Growth Opportunities in the Healthcare and Life Sciences Industry for 2021 – What You Need to Know Now.
Frost & Sullivan
JANUARY 11, 2022
January 11, 2022 – Frost & Sullivan analyzed global digital transformation services in the life sciences industry and, based on its findings, recognizes Capgemin i with the 2021 Global Company of the Year Award for digital transformation services within life sciences.
McKinsey Public & Social Sector Insights
JANUARY 27, 2023
Insights on Life Sciences PharmaceuticalsDigital-native start-ups and healthcare incumbents can both play important roles in building and scaling digital therapeutics to improve the management of chronic health conditions.
McKinsey Public & Social Sector Insights
JANUARY 5, 2023
Insights on Life Sciences PharmaceuticalsGrowth in the availability and variety of real-world data, including nonhealth sources of data, opens up new opportunities, as well as challenges, in their application to real-world evidence and improving health outcomes.
McKinsey Public & Social Sector Insights
JANUARY 26, 2023
Insights on Life Sciences Oncology/Cancer InnovationKite’s CEO discusses the company’s CAR T-cell therapies and what it means to put patients first.
McKinsey Public & Social Sector Insights
DECEMBER 15, 2022
Insights on Life Sciences Medical products AnalyticsMedtech companies are looking to AI and advanced analytics to help retool their commercial models to meet customers’ evolving expectations—but common misunderstandings can delay progress.
McKinsey
JULY 26, 2022
Insights on Life Sciences Health care reformDigital health solutions have the potential to make healthcare more equitable. Here’s how innovators can deliver on that promise.
McKinsey
MARCH 21, 2022
Pharmaceutical and life sciences companies can unlock new opportunities, help underserved patients, and build a cycle of trust. Insights on Life Sciences Health care reform Pharmaceuticals
McKinsey Public & Social Sector Insights
JANUARY 10, 2023
Insights on Life Sciences PharmaceuticalsThe world will need more sterile products than manufacturers have or can build capacity for. But they can create capacity and take market share by running higher volumes through their existing lines.
McKinsey Public & Social Sector Insights
OCTOBER 11, 2022
Insights on Life Sciences BiotechnologyLeveraging digital and analytics advances can unlock significant value for biopharma companies through gains in quality, speed, agility, and resilience.
McKinsey
JUNE 10, 2022
Insights on Life Sciences BiotechnologyFrom 2019 to 2021, venture capitalists plowed $35 billion into biotech companies with advanced platform technologies that could transform the industry.
McKinsey Public & Social Sector Insights
JANUARY 10, 2023
Advances in biological science could help the world overcome its most pressing challenges in health and sustainability. Insights on Life Sciences Health care services Pharmaceuticals Europe Climate changeEurope’s Bio Revolution could translate scientific strengths into impact.
McKinsey Public & Social Sector Insights
OCTOBER 27, 2022
Insights on Life Sciences Health Care PharmaceuticalsThe biopharmaceutical industry has made remarkable achievements in the past decade, but is it equipped to leap still further ahead in the coming one? Company leaders’ answers to nine questions could prove decisive.
McKinsey
DECEMBER 21, 2021
Insights on Life Sciences PharmaceuticalsThe COVID-19 pandemic has prompted pharma companies to rethink their organizational strategies. A survey of executives suggests where value might lie.
McKinsey Public & Social Sector Insights
SEPTEMBER 17, 2022
Insights on Life Sciences Pharmaceuticals InnovationThe sometimes-overlooked function of chemistry, manufacturing, and controls (CMC) has a rare opportunity to reimagine its role and find innovative ways to improve and accelerate drug development.
McKinsey
SEPTEMBER 24, 2021
Insights on Life Sciences Medical products Digital marketing AnalyticsDigital marketing offers medtech companies powerful ways to personalize engagement with healthcare professionals and respond to their changing needs.
McKinsey
APRIL 8, 2022
Harnessing advances in science and technology can deliver transformative therapies faster while reducing the socioeconomic burden of disease. Insights on Life Sciences Biotechnology Innovation
McKinsey Public & Social Sector Insights
SEPTEMBER 20, 2022
Insights on Life Sciences Pharmaceuticals Medical productsRoche Pharmaceuticals’ approach to rare conditions highlights industry efforts to make a difference for patients, their caregivers, and healthcare professionals.
McKinsey
JULY 21, 2022
Insights on Life Sciences Pharmaceuticals JapanPharma companies in Japan have an opportunity to obtain value from real-world evidence using advanced analytics and to better ensure patient outcomes.
McKinsey Public & Social Sector Insights
OCTOBER 11, 2022
Insights on Life Sciences BiotechnologyThe recent market downturn has affected biotechs worldwide. But the fundamentals are still strong in Europe, where companies have an opportunity to lead the next phase of bioscience innovation.
McKinsey
MARCH 15, 2022
Insights on Life Sciences Pharmaceuticals AnalyticsAs pharma companies apply advanced analytics to generate new types of evidence, how do they decide which use cases to target and how to scale them up across the business?
McKinsey
DECEMBER 3, 2021
The United Kingdom is Europe’s leading biotech hub in breakthrough life-sciences start-ups. Insights on Life Sciences Pharmaceuticals Medical products United KingdomHow is this hub maturing relative to its global peers, and what lies ahead on the road to sustainable scale?
McKinsey Public & Social Sector Insights
AUGUST 15, 2022
Insights on Life Sciences PharmaceuticalsChina-originated biopharmas will likely have greater influence on the industry by 2028, but regulatory developments and the quality of partnerships will determine how the industry grows.
McKinsey Public & Social Sector Insights
OCTOBER 10, 2022
Insights on Life Sciences PharmaceuticalsBy focusing on specific scientific and operational pain points and fully integrating AI into research workflows, biopharma companies can deliver greater patient impact and significant value.
McKinsey
APRIL 15, 2022
Insights on Life Sciences Health care services Health Care PharmaceuticalsHealth data platforms that participants trust could bring an end to today’s reductionist approach to drug development, revolutionizing our understanding of disease.
Expert insights. Personalized for you.
70 
Let's personalize your content